New designer proteins created using an AI tool can selectively target peptide segments that bind to markers on diseased ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ...

Consider how immune cells may be tailored to combat any type of cancer. T cell receptor (TCR) therapy has the potential to ...

A case report recently published in the New England Journal of Medicine (NEJM) presents a previously unknown cause of skin ...

Immunologists from UNIGE have discovered the previously unsuspected anti-tumor potential of CD4 T lymphocytes. An important ...

The platform will support Anocca's Phase I/II trial of its therapies under development for treating KRAS-mutated pancreatic cancer.

The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel ...